These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 15598004)
1. Pharmacology of botulinum neurotoxin serotype A. Wenzel RG Am J Health Syst Pharm; 2004 Nov; 61(22 Suppl 6):S5-10. PubMed ID: 15598004 [TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Callaway JE Clin Dermatol; 2004; 22(1):23-8. PubMed ID: 15158541 [TBL] [Abstract][Full Text] [Related]
3. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Aoki KR Headache; 2003; 43 Suppl 1():S9-15. PubMed ID: 12887389 [TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Aoki KR; Guyer B Eur J Neurol; 2001 Nov; 8 Suppl 5():21-9. PubMed ID: 11851731 [TBL] [Abstract][Full Text] [Related]
5. Unlabeled uses of botulinum toxins: a review, part 2. Cheng CM; Chen JS; Patel RP Am J Health Syst Pharm; 2006 Feb; 63(3):225-32. PubMed ID: 16434781 [TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Callaway JE; Arezzo JC; Grethlein AJ Semin Cutan Med Surg; 2001 Jun; 20(2):127-36. PubMed ID: 11474745 [TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Callaway JE; Arezzo JC; Grethlein AJ Dis Mon; 2002 May; 48(5):367-83. PubMed ID: 12195266 [TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products. Dessy LA; Fallico N; Mazzocchi M; Scuderi N Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763 [TBL] [Abstract][Full Text] [Related]
10. Unlabeled uses of botulinum toxins: a review, part 1. Cheng CM; Chen JS; Patel RP Am J Health Syst Pharm; 2006 Jan; 63(2):145-52. PubMed ID: 16390928 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a vertebrate neuromuscular junction that demonstrates selective resistance to botulinum toxin. Coffield JA; Bakry NM; Maksymowych AB; Simpson LL J Pharmacol Exp Ther; 1999 Jun; 289(3):1509-16. PubMed ID: 10336546 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic use of botulinum toxins: background and history. Setler PE Clin J Pain; 2002; 18(6 Suppl):S119-24. PubMed ID: 12569958 [TBL] [Abstract][Full Text] [Related]
13. Studies on the dissociation of botulinum neurotoxin type A complexes. Eisele KH; Fink K; Vey M; Taylor HV Toxicon; 2011 Mar; 57(4):555-65. PubMed ID: 21195107 [TBL] [Abstract][Full Text] [Related]
14. Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses. Charles PD Am J Health Syst Pharm; 2004 Nov; 61(22 Suppl 6):S11-23. PubMed ID: 15598005 [TBL] [Abstract][Full Text] [Related]
15. Recovery from botulinum neurotoxin poisoning in vivo. Keller JE Neuroscience; 2006 May; 139(2):629-37. PubMed ID: 16490322 [TBL] [Abstract][Full Text] [Related]
17. [Mechanism of therapy effects by botulinum neurotoxin]. Alajbegović A; Alajbegović S; Resić H Med Arh; 2008; 62(1):53-5. PubMed ID: 18543757 [TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of botulinum toxin immunogenicity. Benecke R BioDrugs; 2012 Apr; 26(2):e1-9. PubMed ID: 22385408 [TBL] [Abstract][Full Text] [Related]
19. Proper dose, preparation, and storage of botulinum neurotoxin serotype A. Anderson ER Am J Health Syst Pharm; 2004 Nov; 61(22 Suppl 6):S24--9. PubMed ID: 15598006 [TBL] [Abstract][Full Text] [Related]
20. Pharmacology of botulinum toxin. Huang W; Foster JA; Rogachefsky AS J Am Acad Dermatol; 2000 Aug; 43(2 Pt 1):249-59. PubMed ID: 10906647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]